Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
LY2062430
DRUG
3 trials
Sponsors
Eli Lilly and Company
Conditions
Alzheimer's Disease
Phase 2
Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers
Completed
NCT00329082
Eli Lilly and Company
Alzheimer's Disease
Start: 2006-05-31
End: 2008-05-31
Updated: 2009-10-07
Phase 3
Effect of LY2062430 on the Progression of Alzheimer's Disease
Completed
NCT00905372
Eli Lilly and Company
Alzheimer's Disease
Start: 2009-05-31
End: 2012-04-30
Target: 1000
Updated: 2012-09-25
Effect of LY2062430 on the Progression of Alzheimer's Disease
Completed
NCT00904683
Eli Lilly and Company
Alzheimer's Disease
Start: 2009-05-31
End: 2012-06-30
Updated: 2012-12-13
Related Papers
The Alzheimer's Disease Cooperative Study - Activities of Daily Living dependence score: revision and validation of an algorithm evaluating patient dependence across the spectrum of AD severity.
2025-07-01
Representativeness of European clinical trial populations in mild Alzheimer's disease dementia: a comparison of 18-month outcomes with real-world data from the GERAS observational study.
2018-04-03
5 citations
[P1–042]: PLASMA PHARMACOKINETICS AND PHARMACODYNAMICS OF SOLANEZUMAB IN MILD AND MODERATE AD PATIENTS
Alzheimer s & Dementia
2017-07-01
5 citations
[P4–155]: DERIVING A CUT‐OFF FOR THE ELECSYS® β‐AMYLOID (1–42) IMMUNOASSAY FOR USE IN CLINICAL TRIALS SUPPORTED BY ELI LILLY FOR PATIENTS WITH CLINICALLY DEFINED ALZHEIMER's DISEASE (AD)
Alzheimer s & Dementia
2017-07-01
2 citations
[P1–049]: SOLANEZUMAB CENTRAL TARGET ENGAGEMENT AND PHARMACODYNAMIC ACTIVITY IN THE EXPEDITION 3 TRIAL OF PATIENTS WITH MILD AD: COMPARISON TO EXPEDITION/EXPEDITION 2
Alzheimer s & Dementia
2017-07-01
Assessing quality of life in Alzheimer's disease: Implications for clinical trials.
2016-12-13
40 citations
Alzheimer’s disease progression by geographical region in a clinical trial setting
Alzheimer s Research & Therapy
2015-05-13
35 citations
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
New England Journal of Medicine
2014-01-22
1624 citations